clinical and functional consequences associated to a pkp2 founder
TRANSCRIPT
Session: Advances in genetics of cardiomyopathies
Clinical and functional consequences
associated to a PKP2 founder mutation in
north-west Spain
Presenter: Lorenzo Monserrat
Paris, 28 Aug 2011
A. Diez-Juan , MF. Ortiz, L. Perez-Alvarez, R. Barriales-Villa, DA. Garcia, J.
Moncayo-Arlandi, X. Fernandez, L. Nunez, L. Monserrat
Potential conflicts of interest
Lorenzo Monserrat:
Promoter and Stockholder:
Health in Code
•Primary and inherited affection of the myocardium(estimated
prevalence 1:5000 )
•Progressive replacement of right ventricular myocardium with
adipose and fibrous tissue (mainly RV, but also LV)
ARVC
DESMOSOMAL GENES
www.e-heart.org
•25 unrelated index cases with ARVC from A Coruña
(Galicia-Spain)
•Sequence analysis of 4 main desmosomal genes:
•Plakophilin-2 (PKP2)
•Desmoplakin (DSP)
•Desmoglein-2 (DSG2)
•Desmocollin-2 (DSC2)
COHORT
GEOGRAPHICAL DISTRIBUTION
•10 mutations (9 novel) in 17 of 25 pts 68%
•4 pts complex genotypes 16%
•1 homozygous
•1 compound heterozygous
•2 doble heterozygous
•3 mutations in more than 1 proband
•S329RfsX351 in PKP2 (9 cases)
•R375X in DSC2 (2 cases)
•C813R in DSG2 (2 cases)
GENETIC STUDIES
PROBAND PKP2 DSP DSC2 DSG2
1 S329RfsX351
2 S329RfsX351
3* S329RfsX351
E624D
4* S329RfsX351 K468Q
5 S329RfsX351
6* S329RfsX351 R375X
7 S329RfsX351
8 S329RfsX351
9 S329RfsX351
10* R375X (H)
11 IVS11+2T>C
12 M589T
13 IVS9-1G>C
14 R1945C
15 R907L
16 C813R
17 C813R
* Complex genotypes
18 carriers
8 non carriers
49 without
genetic study
9 families
S329RfsX351 – PKP2
8 ARVC
7 possible ARVC
3 not affected or healthy
1 possible ARVC
7 not affected or healthy
1 ARVC
1 possible ARVC
3 not affected or healthy,
44 without phenotypic study
Events in mutation carriers
2 Sudden deaths
4 Appropiate ICD shocks
1 Stroke related death
2 Strokes without death
Events in relatives without genetic study
3 Sudden deaths
2 Stroke related deaths
1 Stroke without death
EVENTS
SD
SD SD
aSD
aSD
ICDs
ICDs
ICDs
ICDs
HCM HCM
Stroke Stroke
x2
Stroke
Stroke
Stroke
Table - Genetic and clinical characteristics of S329RfsX351-PKP2 carriers
Table - Clinical characteristics of relatives without genetic diagnosis who had
adverse events
Fressart et al. Europace 2010;12:861-868
300
healthy
controls
?
PKP2 –
S329RfsX351
•Costa da Morte
(Death coast)
FOUNDER
EFFECT
PKP 2: Constructions
S329fsX351
(pb4086)
Armadillo domain Variable domain
N
´ C
´
hPKP2 V5
Esmeral V5 mPKP2
Esmeral V5 mPKP2
(Control)
Esmeral V5
Experimentals
S329fsX351
EXT
INT
INT
Plakophilin 2
S329fsX351
Control
H9C2
Rat ventricular cardiomyocytes
HL-1
Mouse atrial cardiomyocytes
Neonatal Cardiomyocytes
Rat ventricular cardiomyocytes
Esmeral V5
mPKP2
Esmeral V5 mPKP2
Esmeral V5
hPKP2 V5
S329fsX351
Esmeral V5 mPKP2
S329fsX351
Lentiviral vector
hPKP2
-v5
hPKP2
-v5 Control Control
Cytoplasmic Nuclear
v5
hPKP2
-v5
hPKP2
-v5 Control Control
Cytoplasmic Nuclear
PKP2
hPKP2 V5 mPKP2
Control Control hPKP2-v5 hPKP2-v5
HL-1
Mouse Atrial Cardiomiocytes
α- Tubulin α- Tubulin
Anti V5 Anti C-term
HL-1
Mouse Atrial Cardiomiocytes
Control hPKP2-v5 Control hPKP2-v5
γ-catenin Desmoplakin
Neonatal rat
ventricular
cardiomyocytes
Control hPKP2-v5
Anti-v5
Anti-PKP2
↑↑ PPAR-γ (Adipogenic factor)
↑ TGF-β2 and TGF β3 (Fibrosis factors)
↑ Vimentin (Adipogenic marker)
Fibrosis
factors
Adigogenic
marker
hPKP2 V5
CONCLUSIONS
•Mutations in 70% of ARVC cases
•S329RfsX351-PKP2 is a pathogenic mutation
associated with the development of ARVC
•Founder mutation in Galicia
•Incomplete penetrance in young carriers
•Severe expression in cases with additional
pathogenic mutations
•Arrhythmic sudden death and strokes
•LV involvement relatively common
CONCLUSIONS
•Functional studies:
•PKP2 not only a structural protein
•Nuclear localization of mutant PKP2 could
be responsible of anomalous cardiomyocyte
gene expression
•Support for a role for immunofluorescence
studies in the diagnosis of ARVC (Asimaki et al)